Ear-Based Vagus Nerve Stimulation for Autonomic Regulation: Info Guide Released

Nurosym releases a new guide detailing ear-based vagus nerve stimulation as a medicinal approach, highlighting its own CE-marked wearable device as a viable example backed by research on stress, energy, and nervous system regulation.

London, United Kingdom, October 11, 2026 /PressCable/ -- Nurosym has published a guide explaining how ear-based vagus nerve stimulation can support autonomic regulation. The document also outlines the science behind Parasym's proprietary AVNT™ technology in support of those seeking non-pharmaceutical approaches to stress, energy, and nervous system health.

For more information, visit: https://nurosym.com/blogs/articles/vagus-nerve-ear-stimulation

As explained in the new guide, the vagus nerve carries signals between the brain and organs such as the heart, lungs, and gut - playing a vital role in how the body manages stress, rest, and recovery. Moreover, with the ear offering direct access to this nerve, the placement and method of stimulation used is said to weigh heavily on how the system responds.

For its own part, Nurosym applies this principle through a small wearable VNS device. Briefly put, an earpiece clips onto the tragus (the part of the outer ear closest to the ear canal where the vagus nerve reaches the skin's surface) and delivers gentle electrical pulses using Parasym's proprietary AVNT™ waveform.

According to the company, the device requires no gel and no clinic visit - allowing it to fit into ordinary daily routines such as working or reading. The potential benefits, suggests Parasym’s Head of Research Dr. Elisabetta Burchi, are considerable:

“By offering accessible, wearable and targeted treatment options, the non-invasive neuromodulatory approach can safely be combined with pharmacotherapy for a wide range of neurological, psychiatric, metabolic and inflammatory conditions to potentially revolutionise care for patients who haven't responded well to traditional therapies.”

Nurosym’s document points to a body of research behind the movement. In fact, Parasym reports that its own AVNT-driven technology is backed by more than 60 completed clinical studies, over 100 ongoing studies, and more than 150 research partners to complement more than a decade of prior research and development. Nurosym also holds CE marking - a label described as a confirmation that the device meets recognised standards for safety and performance within European regulatory frameworks.

Interested parties can find further details about Nurosym's specific approach to neuromodulation and autonomic health at: https://nurosym.com/

Disclaimer: Research referenced in this article was conducted using Parasym's neuromodulation technology under research conditions. Findings relate to specific study populations and should not be interpreted as medical claims or guaranteed individual outcomes. Nurosym is a CE-marked medical device in Europe.

Contact Info:
Name: PR Team
Email: Send Email
Organization: Nurosym by Parasym
Address: 18 Saint Cross Street 4th Floor, London, England EC1N 8UN, United Kingdom
Website: https://nurosym.com/

Source: PressCable

Release ID: 89205737

If you encounter any issues, discrepancies, or concerns regarding the content provided in this press release, or if there is a need for a press release takedown, we urge you to notify us without delay at [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our expert team will be available to promptly respond within 8 hours – ensuring swift resolution of identified issues or offering guidance on removal procedures. Delivering accurate and reliable information is fundamental to our mission.